Stock Analysis
Shionogi (TSE:4507) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥435.1b (up 2.0% from FY 2023).
- Net income: JP¥162.0b (down 12% from FY 2023).
- Profit margin: 37% (down from 43% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: JP¥559 (down from JP¥621 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shionogi Revenues Disappoint
Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are up 3.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Shionogi that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether Shionogi is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Shionogi is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4507
Shionogi
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
Very undervalued with flawless balance sheet and pays a dividend.
